A retrospective analysis of clinical reports of gliomas confirmed that CD44 expression was significantly predictive of shorter overall survival in patients with WHO grade II and III gliomas but not in patients with glioblastomas [82]. This evidence concerns the gene CD44 and central nervous system cancer.